Friday, November 13, 2026

Federal Reserve to Pause Rate Cuts by Early 2026, Reshaping Global Borrowing Costs

The US Federal Reserve will likely halt interest rate reductions by early 2026, ending a two-year easing cycle with 82% probability. The shift follows persistent inflation risks and resilient growth, affecting borrowing costs worldwide as central banks from Europe to Asia adjust policies in response to Fed decisions.

LM Salvado
LM Salvado

March 16, 2026

Federal Reserve to Pause Rate Cuts by Early 2026, Reshaping Global Borrowing Costs
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

The Federal Reserve will pause rate cuts by early 2026 with 82% confidence, halting an easing cycle that began in 2024. The decision reverberates globally as the dollar's dominance makes Fed policy a de facto anchor for central banks from Frankfurt to Tokyo.

Three factors drive the pause. Inflation threatens to breach the 2% target despite earlier cooling. US economic growth outpaces forecasts, reducing stimulus needs. Financial stability concerns emerge as prolonged low rates inflate asset valuations across markets.

International implications extend beyond American borders. The European Central Bank and Bank of England face diverging pressures—cutting rates to stimulate sluggish economies while monitoring Fed moves that strengthen the dollar and import inflation. Emerging markets from Brazil to South Africa confront capital outflows as higher US rates attract investor funds.

Banking sectors worldwide must recalibrate. European lenders already squeezed by negative rates gain breathing room as margins stabilize. Asian banks serving export economies face tighter lending conditions as dollar funding costs rise. Cross-border lending markets reprice risk as currency volatility increases.

Corporate borrowers globally rush to secure financing. Multinationals that delayed bond issues anticipating cheaper rates accelerate issuance before costs firm. Mortgage markets from Canada to Australia adjust as rate expectations shift, cooling property demand in overheated cities.

Credit markets signal uncertainty through yield curve movements. US Treasury rates influence sovereign debt pricing worldwide—a pause would stabilize short-term rates while long-dated bonds reflect inflation fears. Developing nations with dollar-denominated debt face higher refinancing burdens.

This pause differs from 2019's mid-cycle adjustment. It arrives amid coordinated fiscal expansion across G7 economies, persistent supply chain disruptions, and geopolitical tensions from Ukraine to Taiwan. Central banks lack the synchronized easing that defined previous decades.

Fed Chair Jerome Powell's statements carry outsized global weight. Currency traders in London, bond desks in Hong Kong, and treasury departments in São Paulo parse FOMC minutes for timing signals. Market volatility typically spikes during US policy transitions as international capital repositions across asset classes and borders.

In this story · Knowledge Files

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com